Targeting Inflammasomes in HIV and Substance Use (R21 Clinical Trial Not Allowed)

The summary for the Targeting Inflammasomes in HIV and Substance Use (R21 Clinical Trial Not Allowed) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Targeting Inflammasomes in HIV and Substance Use (R21 Clinical Trial Not Allowed): The scientific objective of this Notice of Funding Opportunity is to encourage research to delineate the role of inflammasomes in the neuropathology produced by acute or chronic drug exposure and HIV infection. Understanding the involvement of inflammasomes in virus and drug-induced immune activation may help identify molecular markers and CNS immune cells associated with HIV-1 infection or disease progression among substance abuse populations, as well as identify novel therapies to target inflammasome activation or suppression to treat neuroinflammation and immune dysregulation aroused in these processes.
Federal Grant Title: Targeting Inflammasomes in HIV and Substance Use (R21 Clinical Trial Not Allowed)
Federal Agency Name: National Institutes of Health (HHS-NIH11)
Grant Categories: Education, Health
Type of Opportunity: Discretionary
Funding Opportunity Number: RFA-DA-25-068
Type of Funding: Grant
CFDA Numbers: 93.279
CFDA Descriptions: Information not provided
Current Application Deadline: March 13th, 2025
Original Application Deadline: March 13th, 2025
Posted Date: October 29th, 2024
Creation Date: October 29th, 2024
Archive Date: April 18th, 2025
Total Program Funding:
Maximum Federal Grant Award: $500,000
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching: No
Last Updated: October 29th, 2024
Applicants Eligible for this Grant
State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For-profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification.)
Additional Information on Eligibility
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Link to Full Grant Announcement
https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-068.html
Grant Announcement Contact
NIH Grants Information
[email protected]
See Section VII. Agency Contacts within the full opportunity announcement for all other inquires.
Similar Government Grants
Engaging Loved ones in Recovery Processes to Enhance Recovery Capital and Outcomes (R61/R3...
Addressing Challenges in Detecting New Drugs: Instrumentation for Alternative Analytical M...
Addressing Challenges in Detecting New Drugs: Instrumentation for Alternative Analytical M...
Targeting Inflammasomes in HIV and Substance Use (R01 Clinical Trial Not Allowed)
Ending the Epidemic: New Models of Integrated HIV/AIDS, Addiction, and Primary Care Servic...
NIDA Phase II Small Business Innovation Research (SBIR [R44]) Competing Renewal Awards
Drug Abuse Aspects of Hiv/Aids and Other Infections
Epidemiology of Drug Abuse
More Grants from the National Institutes of Health
Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems (...
Bioengineering Partnerships with Industry (U01 Clinical Trial Optional)
Engineering Next-Generation Human Nervous System Microphysiological Systems (R21 Clinical ...
Engineering Next-Generation Human Nervous System Microphysiological Systems (R01 Clinical ...
Assay Development and Screening for Discovery of Validated Chemical Hits for Brain Disorde...

FederalGrants.com is not endorsed by, or affiliated with, any government agency. Copyright ©2007-2024 FederalGrants.com